Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma Journal Article

Local Library Link: Find It @ Loyola

Authors: Alva, A.; Daniels, G. A.; Wong, M. K.; Kaufman, H. L.; Morse, M. A.; McDermott, D. F.; Clark, J. I.; Agarwala, S. S.; Miletello, G.; Logan, T. F.; Hauke, R. J.; Curti, B.; Kirkwood, J. M.; Gonzalez, R; Amin, A; Fishman, M.; Agarwal, N.; Lowder, J. N.; Hua, H.; Aung, S.; Dutcher, J. P.
Article Title: Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
Abstract: High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era predating targeted therapies and immune checkpoint inhibitors. The PROCLAIMSM registry was established to collect and analyze data for patients treated with HD IL-2 in the current era. This analysis includes 170 patients with mM and 192 patients with mRCC treated between 2005 and 2012 with survival data current as of July 27, 2015. For patients with mM, complete response (CR) was observed in 5 %, partial response (PR) in 10 %, stable disease (SD) in 22 %, and 63 % had progressive disease (PD). The median overall survival (mOS) for these patients was 19.6 months, with a median follow-up of 43.1 months. The mOS was not reached for patients achieving CR or PR, and was 33.4 months for patients with SD. For patients with mRCC, 6 % achieved CR, 9 % had PR, 22 % had SD, and 62 % had PD. The mOS was 41 months, with a median follow-up of 46.6 months. The mOS for patients who had CR and PR was not reached and was 49.6 months for patients with SD. There were no treatment-related deaths among 362 patients. The duration of mOS for patients with mM and mRCC is longer than historically reported. These data support a continued role for IL-2 in the treatment of eligible patients with mM or mRCC and warrant further evaluation of HD IL-2 in combination or sequence with other therapeutic agents.
Journal Title: Cancer immunology, immunotherapy : CII
ISSN: 1432-0851; 0340-7004
Publisher: Unknown  
Journal Place: Germany
Date Published: 2016
Language: ENG
DOI/URL:

10.1007/s00262-016-1910-x
Notes: LR: 20161008; JID: 8605732; OTO: NOTNLM; 2015/10/27 [received]; 2016/09/29 [accepted]; aheadofprint